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Abstract
Background: Olvanil (NE 19550) is a non-pungent synthetic analogue of capsaicin, the natural pungent ingredient
of capsicum which activates the transient receptor potential vanilloid type-1 (TRPV1) channel and was developed as
a potential analgesic compound. Olvanil has potent anti-hyperalgesic effects in several experimental models of
chronic pain. Here we report the inhibitory effects of olvanil on nociceptive processing using cultured dorsal root
ganglion (DRG) neurons and compare the effects of capsaicin and olvanil on thermal nociceptive processing in
vivo; potential contributions of the cannabinoid CB1 receptor to olvanil’s anti-hyperalgesic effects were also
investigated.
Methods: A hot plate analgesia meter was used to evaluate the anti-nociceptive effects of olvanil on capsaicin-induced
thermal hyperalgesia and the role played by CB1 receptors in mediating these effects. Single cell calcium imaging studies
of DRG neurons were employed to determine the desensitizing effects of olvanil on capsaicin-evoked calcium responses.
Statistical analysis used Student’s t test or one way ANOVA followed by Dunnett’s post-hoc test as appropriate.
Results: Both olvanil (100 nM) and capsaicin (100 nM) produced significant increases in intracellular calcium
concentrations [Ca2+]i in cultured DRG neurons. Olvanil was able to desensitise TRPV1 responses to further capsaicin
exposure more effectively than capsaicin. Intraplantar injection of capsaicin (0.1, 0.3 and 1 μg) produced a robust TRPV1-
dependant thermal hyperalgesia in rats, whilst olvanil (0.1, 0.3 and 1 μg) produced no hyperalgesia, emphasizing its lack
of pungency. The highest dose of olvanil significantly reduced the hyperalgesic effects of capsaicin in vivo. Intraplantar
injection of the selective cannabinoid CB1 receptor antagonist rimonabant (1 μg) altered neither capsaicin-induced
thermal hyperalgesia nor the desensitizing properties of olvanil, indicating a lack of involvement of CB1 receptors.
Conclusions: Olvanil is effective in reducing capsaicin-induced thermal hyperalgesia, probably via directly desensitizing
TRPV1 channels in a CB1 receptor-independent fashion. The results presented clearly support the potential for olvanil in
the development of new topical analgesic preparations for treating chronic pain conditions while avoiding the unwanted
side effects of capsaicin treatments.
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Background
TRPV1 (transient receptor potential vanilloid type 1) is a
chemically-gated non-specific cation channel with high cal-
cium permeability [1], which integrates a range of painful
stimuli including noxious heat (>43 ° C) [2] and low pH [3]
and which responds to pungent compounds, such as capsa-
icin [2, 4]. TRPV1 is widely distributed throughout the cen-
tral [5] and peripheral nervous systems [6]. It is well
established that TRPV1 is a key molecule involved in the
progress of many chronic pain conditions such as those as-
sociated with inflammation, cancer and neuropathy [7–10].
As a consequence, TRPV1 is viewed as a prime target for
pharmacological intervention to control pain. Although the
development of TRPV1 antagonists has been a logical step
forward for developing new analgesics, their clinical benefit
is limited by unwanted side effects including effects on core
body temperature [11–13].
The increase in intracellular calcium concentration
([Ca2+]i) mediated by TRPV1 is essential to induce
neurotransmitter release from the primary afferent
fibres. However, elevation of [Ca2+]i through TRPV1
activation leads to desensitization of the channel,
probably through calcium-dependent mechanisms in-
cluding Ca2+/calmodulin and the Ca2+-sensitive phos-
phatase calcineurin [14, 15]. Desensitization of
TRPV1, which occurs after the calcium entry, provides
a feedback mechanism to regulate calcium homeosta-
sis and is the basis of the use of TRPV1 agonists as
analgesics as an alternative approach to TRPV1 antag-
onism. Indeed, topical preparations containing low
concentrations of capsaicin have long been used as
over-the-counter remedies for pain.
Clinical trials have demonstrated that capsaicin is ef-
fective in alleviating pain associated with osteoarthritis
[16], and a synthetic, orally active isomer of capsaicin,
civamide, was reported to significantly reduce cluster
headache [17] and migraine headache [18]. High-
concentration topical capsaicin (8 % patch; Qutenza®) is
licensed in the EU to treat neuropathic pain in non-
diabetic patients, and in the US to treat peripheral her-
petic neuralgia. Treatment can give rise to a long-lasting
effect, which has been termed ‘defunctionalisation’, prob-
ably owing to a number of different effects that, together,
overwhelm neuronal homeostasis, leading to reversible
degeneration of nerve terminals [19]. However, the use
of TRPV1 agonists like capsaicin is hindered by the ini-
tial sharp and burning sensation, referred to as pungency
which requires patches to be available for use only by
specialist healthcare workers and needs pre-treatment
with local anesthetic.
Development of non-pungent capsaicin analogues
such as olvanil, palvanil and arvanil with retention of an-
algesic properties could be of significant clinical value.
Previous studies explored differences between pungent
and non-pungent TRPV1 agonists, and proposed various
hypotheses to explain the translation of these differences
in in vivo pungency. Interestingly, none of the previous
reports evaluated the effects of the non-pungent TRPV1
agonist olvanil on the capsaicin-evoked calcium re-
sponses in isolated DRG neurons, which may have an
important physiological relevance in particular to
TRPV1 desensitization and the subsequent neurotrans-
mitter release. Furthermore, the contribution of CB1
cannabinoid receptors to the analgesic effects of olvanil
in vivo remains unclear, as the previous reports were fo-
cused solely on in vitro studies using cell lines. The aim
of the current study was to fill in these gaps and test the
anti-hyperalgesic effects of olvanil and to further study
the potential role for cannabinoid receptors in mediating
these analgesic effects. To address the mechanism of the
desensitizing effects of olvanil on the capsaicin-evoked
hyperalgesia, calcium responses in isolated DRG neurons
were also evaluated.
Methods
Animals
Calcium imaging experiments used adult male
Sprague Dawley rats (180–200 g, Charles River UK).
Rats were group housed in the Biomedical Services
Unit (University of Nottingham) in a temperature con-
trolled environment 22 ± 1 °C at 12 h: 12 h light: dark
cycle. Behavioural experiments used adult male albino
rats (180–200 g, The University of Jordan laborator-
ies). Procedures were approved by the University of
Nottingham Ethical Review Committee and by the sci-
entific research committee at the University of Jordan.
Experiments were carried out in accordance with the
Animal (Scientific Procedure) Act 1986 and Inter-
national Association for the Study of Pain guidelines.
Calcium imaging of dorsal root ganglion neurons
A total of 16 rats, killed by CO2 overdose, were used for
the calcium imaging studies. Spinal columns were re-
moved and dorsal root ganglia (DRGs) neurons were
collected [20]; cell preparation and culture were as de-
scribed previously [21, 22].
Cells were washed three times with calcium imaging
buffer (NaCl, 145 mM; KCl, 5 mM; CaCl2, 2 mM;
MgSO4.7H2O, 1 mM; HEPES, 10 mM; glucose, 10 mM;
pH, 7.4). Then cells were loaded with 5 μl of Fura2-AM
in 895 μl of calcium buffer with 100 μl of fetal calf
serum (FCS) and incubated for 30 min in the dark. Cells
were washed with calcium buffer and left for at least
15 min prior to imaging. [Ca2+]i was measured as the ra-
tio of peak fluorescence emission intensities (measured
at 500 nm) at excitation wavelengths of 340 nm and
380 nm, respectively, using an Andor IQ imaging system
and expressed as changes in relative fluorescence units
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(ΔRU). Coverslips were fixed to a Perspex chamber
using vacuum grease, and the DRG neurons were supra-
fused with calcium buffer at a rate of 2 ml/min. All
drugs were applied by suprafusion in calcium buffer.
Effects of olvanil on capsaicin-evoked calcium responses
Experiments were designed so that DRG cells were not
exposed to capsaicin more than three times. A standard
protocol was followed in which DRG cells were exposed
to capsaicin (100 nM) for 1 min followed by a 45 min
wash-out period. Olvanil (100 nM) was then suprafused
for 1 min followed by another 45 min of wash-out. Fi-
nally, cells were re-exposed to capsaicin (100 nM for
1 min) followed by 45 min of wash-out. This protocol
was followed based on the observation that the majority
of capsaicin-evoked calcium responses returned to base-
line values after a 45 min wash-out period, as previously
reported [22, 23].
To determine whether TRPV1 desensitization could
have been a confounding factor, parallel control experi-
ments were conducted in which DRG cells were chal-
lenged three times with capsaicin, using the same timing
schedule as described above (capsaicin exposure sepa-
rated by a 45 min wash-out period). A depolarizing con-
centration of KCl (60 mM) was applied at the end of
each experiment to confirm neuronal responsiveness.
KCl responding cells that had a peak 340:380 nm ratio
of more than 0.10 and were at least 0.2 fluorescence
units above the baseline were included in the analysis.
Peak ratios were calculated by subtracting the baseline
ratio from the ratio obtained during drug suprafusion
(ΔRU; ratio units difference). Results are expressed as a
percentage of the peak response evoked by the first cap-
saicin application and presented as mean ± SEM. For
each of the drug application protocols performed for cal-
cium imaging, DRG cells were collected from three to
five rats, and at least one coverslip of DRG cells from
each rat was used for each experiment.
Hot plate testing
Rats were placed individually on a hot plate analgesia
meter (Columbus instruments, USA) maintained at a
constant temperature of 55 ± 0.1 °C after observing them
for 5 min in the cage [24]. The paw withdrawal latency
(PWL) was recorded as the time taken to exhibit distinct
pain behaviour either by hindpaw licking or hindpaw
flicks (whichever occurred first). Rats that did not re-
spond within 30 s were removed from the hot plate to
prevent tissue damage [25].
Capsaicin-induced thermal hyperalgesia
After determining the baseline latencies, rats received
intraplantar injections of capsaicin (0.1, 0.3 and 1 μg in
100 μL of PBS or vehicle) under brief ether anesthesia.
Thermal paw withdrawal latencies (PWL) were then de-
termined at 10, 30 and 100 min after capsaicin injection.
Data are presented as percentages of the baseline PWL
(% PWL =Observed PWL / Baseline PWL × 100).
Pharmacological treatments
For the assessments of the effects of different drugs on
the capsaicin-induced thermal hyperalgesia, olvanil (0.1,
0.3 and 1 μg), 1 μg capsazepine, 1 μg rimonabant (a se-
lective cannabinoid CB1 receptor antagonist) or olvanil
(0.3 μg) plus rimonabant (1 μg) were injected 15 min
prior to capsaicin; all drugs were dissolved in 50 μl of
PBS, except capsaicin which was dissolved in 100 μl of
PBS as described above. The maximum hyperalgesic ef-
fect of capsaicin was observed 10 min post-injection;
therefore, all nociceptive testing was done 10 min fol-
lowing capsaicin administration.
Drugs
Capsaicin, capsazepine, olvanil and rimonabant were pur-
chased from Tocris Bioscience (UK). Drugs were initially
dissolved in ethanol (100 %) to form a stock solution (cap-
saicin 1 mM, capsazepine 10 mM, olvanil 10 mM and
rimonabant 10 mM), then diluted in phosphate-buffered
saline (PBS). Final ethanol concentrations in the solutions
used in the present study did not exceed 0.1 %.
Data analysis
Calcium imaging data are presented as a means ± SEM of
percentage of the peak responses evoked by the first capsa-
icin application, and statistical analysis (Prism 5, GraphPad
Software Inc., La Jolla, CA, USA) used Student’s t-tests.
For the studies measuring capsaicin-induced thermal
hyperalgesia data are presented as means ± SEM of per-
centages of the baseline PWL (% PWL=Observed PWL/
Baseline PWL× 100), and statistical analysis (Prism 5,
GraphPad) used one way ANOVA test followed by Dun-
nett’s post-hoc test as appropriate.
Results
Capsaicin-induced thermal hyperalgesia
In the in vivo behavioral studies, intra-plantar injection of
capsaicin produced a dose- and time-dependent hyper-
algesia (Fig. 1). At all doses tested, the peak hyperalgesic
effect was at 10 min post-injection, with the paw with-
drawal latencies returning to baseline levels by 100 min
post-injection.
To test whether the hyperalgesic effects of capsaicin
were TRPV1 receptor-mediated, the TRPV1 receptor an-
tagonist capsazepine (1 μg) was injected into the ipsilat-
eral hindpaw of the rat 15 min prior to capsaicin.
Capsazepine significantly attenuated capsaicin-induced
thermal hyperalgesia (Fig. 2).
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To test whether an endogenous cannabinoid tone mod-
ulates the capsaicin-evoked thermal hyperalgesia, the se-
lective CB1 antagonist rimonabant (1 μg) was injected into
the ipsilateral hindpaw of the rat 15 min prior to capsa-
icin. Unlike capsazepine, rimonabant had no significant ef-
fect on capsaicin-induced thermal hyperalgesia (Fig. 3).
In contrast to capsaicin, intra-plantar injection of olvanil
(0.1, 0.3 and 1 μg) did not alter thermal nociceptive
thresholds, confirming its lack of pungency (Fig. 4). Inter-
estingly, intra-plantar injection of olvanil (1 μg) signifi-
cantly attenuated capsaicin-evoked thermal hyperalgesia
(Fig. 5). In order to evaluate the possible role of CB1
Fig. 1 Effects of intraplantar injection of different doses of capsaicin on thermal paw withdrawal latency. Data are expressed as mean ± SEM of %
PWL and analyzed using one way ANOVA test followed by Dunnett’s post-hoc, all doses of capsaicin were compared to vehicle at 10 min after
injection (**P < 0.01, ***P < 0.001, n = 7 rats per group)
Fig. 2 Effects of intraplantar injection of capsazepine (1 μg) on capsaicin-induced thermal hyperalgesia. Rats received intraplantar injections of capsazepine,
or vehicle 15 min prior to capsaicin. Data are expressed as mean ± SEM of %PWL and analyzed using Student’s t test, (**P< 0.005, n= 7 rats per group)
Alsalem et al. BMC Pharmacology and Toxicology  (2016) 17:31 Page 4 of 11
receptors in these inhibitory effects of olvanil, 1 μg rimo-
nabant was co-administered with olvanil, The CB1 antag-
onist did not significantly alter the inhibitory effect of
olvanil on capsaicin-evoked thermal hyperalgesia (Fig. 5).
Olvanil attenuates capsaicin-evoked calcium responses
Capsaicin produced a robust increase in [Ca2+]i com-
pared to basal (0.625 ± 0.03 ΔRU, n = 76 neurons, Fig. 6).
To ensure that studies were not compromised by
desensitization of TRPV1, effects of repeated application
of capsaicin were studied. A second capsaicin challenge
in the presence of vehicle (0.01 % ethanol in PBS)
evoked a calcium response of 80.8 ± 2.3 % of the preced-
ing capsaicin-evoked response. A third capsaicin chal-
lenge evoked a calcium response of 77.2 ± 2.2 % of the
first capsaicin-evoked response. Statistical analysis re-
vealed no significant differences between the second and
third exposures to capsaicin (Fig. 7).
Fig. 3 Effects of intraplantar injection of rimonabant (1 μg) on capsaicin-induced thermal hyperalgesia. Rats received intraplantar injections of
rimonabant or vehicle 15 min prior to capsaicin. Data are expressed as mean ± SEM of %PWL and analyzed using Student’s t test (n = 7 rats
per group)
Fig. 4 Effects of intraplantar injection of capsaicin (0.3 μg), olvanil (0.1, 0.3 and 1 μg), or vehicle on paw withdrawal latency. Data are expressed as
mean ± SEM of % PWL and analyzed using one way ANOVA test followed by Dunnett’s post-hoc, all treatments were compared to vehicle at
10 min after injection (*P < 0.05, n = 7 rats per group)
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Olvanil produced a robust increase in [Ca2+]i over basal
(0.566 ± 0.04 ΔRU, n = 128 neurons). Pre-exposing the cells
to the potent selective TRPV1 antagonist 5′-iodoresinifera-
toxin (1 μM) completely blocked both capsaicin and
olvanil-evoked calcium responses (data not shown). Statis-
tical analysis revealed no significant differences between
capsaicin-evoked calcium responses (0.625 ± 0.03 ΔRU, n =
76 neurons) and olvanil-evoked calcium responses (0.566 ±
0.04 ΔRU, n = 128 neurons, P value = 0.26) at the same
concentration (100 nM); however, capsaicin-evoked
calcium responses were significantly inhibited in cells
pre-treated with olvanil (31.6 ± 2.6 % of the first capsaicin-
evoked calcium response) compared to vehicle pre-
treatment (77.2 ± 2.2 %, Figs. 6 and 7).
In order to investigate whether the ability of olvanil to
reduce the subsequent effects of capsaicin was simply
due to a persistent desensitization of TRPV1, we studied
the effect of repeated applications of olvanil on the DRG
neurons. A second application of olvanil in the presence
of vehicle (0.01 % ethanol) evoked a calcium response of
60.2 ± 1.6 % of the preceding olvanil-evoked calcium
response (Fig. 8).
Discussion
In the present study we investigated the anti-
hyperalgesic effects of olvanil in a model of thermal
hyperalgesia which employed capsaicin as an agent that
directly activates TRPV1 on primary sensory neurons. In
parallel, by means of single cell ratiometric calcium im-
aging experiments, we investigated TRPV1 receptor
desensitization following exposure to olvanil.
In agreement with previous reports [26–28], intraplantar
injection of capsaicin produced a robust thermal hyperalge-
sia in a TRPV1-dependent manner. After confirming the
lack of pungency of olvanil using the same model, we
showed that olvanil inhibited the hyperalgesic effects of
intraplantar injection of capsaicin. Based on previous re-
ports suggesting that olvanil may behave as a CB1 receptor
agonist [29] we explored the mechanisms that underlie the
anti-hyperalgesic effects of olvanil by evaluating the poten-
tial role of the CB1 receptor in mediating these effects of
olvanil. The hypothesis that other receptors activated by
olvanil, but not capsaicin, such as the cannabinoid CB1 [29]
may account for the differences between these agonists in
terms of pungency and could conceivably explain the anti-
hyperalgesic effects of olvanil. However, the CB1 antagonist
rimonabant did not alter the analgesic effects of olvanil, ex-
cluding a role for CB1 in mediating these effects in vivo.
This is in spite of previous in vitro studies using cell lines
that reported olvanil binding to CB1 receptors and inhib-
ition of adenylyl cyclase leading to reduction of cAMP
levels in N18TG2 neuroblastoma cells [30]. In addition,
Fig. 5 Effects of intraplantar injection of various doses of olvanil and rimonabant (1 μg) on capsaicin-induced thermal hyperalgesia. Rats received
intraplantar injection of olvanil (Olv; 0.1, 0.3 and 1 μg) or a combination of 0.3 μg olvanil/1 μg rimonabant or vehicle 15 min prior to capsaicin (Caps). Data
are expressed as mean ± SEM of % PWL and analyzed using one way ANOVA test followed by Dunnett’s post-hoc, different treatments were compared to
vehicle at 10 min after injection (*P< 0.05, n= 7 rats per group)
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olvanil has been shown to inhibit transport of the endocan-
nabinoid anandamide into RBL-2H3 cells and to inhibit the
hydrolysis of anandamide by FAAH, the principal endocan-
nabinoid metabolizing enzyme [29, 31]. The inability of
rimonabant to attenuate the analgesic effects of olvanil sug-
gests that activation of the endocannabinoid system, which
has a well-documented inhibitory effect on sensory nerve
function and TRPV1 activity, is unlikely to account for the
differences between the pungency of olvanil and capsaicin,
and, to the best of our knowledge, this is the first report
evaluating the contribution of CB1 receptors to the effects
of olvanil in vivo. In a recent study evaluating analgesic
A
B
Fig. 6 Representative traces illustrating changes in 340/380 nm ratios in DRG cells responding to capsaicin and olvanil. a The cell was suprafused
with capsaicin (100 nM for 1 min) three times separated by 45 min of wash-out with calcium buffer. b The cell was exposed to capsaicin (100
nM) for 1 min, 45 min later, olvanil (100 nM) was applied for 1 min followed by another 45 min of wash-out. Finally, the cell was exposed again
to capsaicin (100 nM for 1 min) followed by 45 min of wash-out
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effects of olvanil on migraine, olvanil reduced spontaneous
and stimulus-induced activity within the trigeminocervical
complex; whereas it had no effect on cortical spreading de-
pression; an effect mediated by both TRPV1 and CB1 [32].
To further explore the mechanisms that could mediate
the anti-hyperalgesic effects of olvanil, we studied its ef-
fects on the capsaicin-evoked calcium responses in iso-
lated DRG neurons. Despite both olvanil and capsaicin
producing a robust increase in [Ca2+]i in cultured dorsal
root ganglion cells, olvanil was more effective than capsa-
icin at producing a desensitisation of TRPV1 to further
capsaicin exposure. This finding along with a similar find-
ing that the non-pungent capsaicin analogue palvanil pro-
duced a greater desensitising effect of TRPV1 compared
to capsaicin [33], suggests that the desensitisation of the
TRPV1 channel is not only dependant on the amount of
agonist-stimulated calcium influx [34, 35], but also on the
type of agonist applied. In line with this proposal, Xu and
co-workers (2005) have shown that camphor, the active
ingredient of many traditional balms and liniments, desen-
sitizes TRPV1 in a calcium-independent fashion by acti-
vating TRPV1 via channel regions distinct from those
affected by capsaicin [36]. Differences in the lipophilicity
of the non-pungent TRPV1 agonists were previously sug-
gested to explain the variation between them in vivo, in
which highly lipophilic compounds were proposed to
cause only a small Ca2+ influx via TRPV1 expressed in the
plasma membrane, but not to be able to activate TRPV1
in the endoplasmic reticulum, in contrast to capsaicin
(less lipophilic) which can activate both [37]. This obser-
vation is unlikely to explain the differences between olva-
nil and capsaicin responses in the present study as both
induced similar calcium responses in DRG cells. This con-
clusion is supported by the finding that piperine, a pun-
gent TRPV1 agonist causes a more marked desensitisation
of TRPV1 compared to capsaicin even in a calcium-free
medium [38]. Both piperine and capsaicin produce cal-
cium influx in DRG cells [39], yet they do not cause the
same neuroinflammatory peptides to be released. Capsa-
icin induces the release of substance P, serotonin and
cholecystokinin, whereas piperine induces the release of
substance P but not serotonin or cholecystokinin [40].
These differences in neurotransmitter release by different
TRPV1 agonists may contribute to the differences in ef-
fects of olvanil and capsaicin in vivo. This concept is sup-
ported by a previous study showing that capsaicin induces
a marked release of calcitonin gene related peptide
(CGRP) while olvanil produces no detectable release of
CGRP in rat spinal cord [41]. In agreement with the anti-
hyperalgesic effects of olvanil observed in the present
study, olvanil significantly reduced the release of CGRP
evoked by depolarizing K+ stimulus [41]. These studies
and the present findings clearly question the correlation
between the calcium signals evoked by the TRPV1 ago-
nists and their subsequent physiological effects.
In spite of the structural similarity between olvanil and
capsaicin which suggests a similar mechanism of action,
multiple agonist binding sites for these agonists could
explain the differences observed between their responses
in vivo, especially when considering the fact that TRPV1
is likely to present as a tetrameric complex [42]; there-
fore, different agonists could recruit more TRPV1 sub-
units or have alternative binding sites on the TRPV1
channel complex.
One limitation of our calcium imaging experiments is
that they were performed on the cell bodies of primary
afferent neurons (as in the majority of the previous stud-
ies using DRG) as axons are removed in the isolation
Fig. 7 Capsaicin-evoked calcium responses in the whole population
of DRG cells in the presence or absence of olvanil. Results are
expressed as a percentage of the peak responses evoked by the first
capsaicin application and are presented as means ± SEM. a, TRPV1-
mediated calcium responses due to repeated exposure to capsaicin
100 nM. b olvanil significantly decreased the capsaicin-evoked calcium
responses compared to an identical protocol of repeated capsaicin
exposure in the presence of vehicle (***P < 0.001, Student’s t test)
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process, raising the possibility that the TRPV1 channels
expressed in the cell body have different properties from
those expressed in the nerve terminals, as was recently
proposed [43]. In this previous study, pungent com-
pounds such as capsaicin and piperine amplified the glu-
tamatergic spontaneous excitatory synaptic transmission
in spinal substantia gelatinosa neurons, while olvanil,
even at a very high concentration (10 μM), had a min-
imal effect. Thus, it is possible that pungent and non-
pungent agonists could have similar effects on the cell
body TRPV1 channels but might (in the case of pungent
agonists) or might not (in the case of non-pungent
agents) be able to generate action potentials, and subse-
quently nociceptive signals, when applied to TRPV1
expressed on the sensory nerve terminals. This possibil-
ity was recently studied in vagal C- fibres, in which the
authors showed that jugular C-fibres have different cap-
acities to transport particular TRPV1 agonists across cell
membranes in the nerve terminals to intracellular bind-
ing sites, while the effects of different agonists on sen-
sory nerve cell bodies were the same [44]. This
undoubtedly needs to be verified in more integrated
neuronal preparations in which measurements of [Ca2+]i
and applications of different agonists take place in the
neuronal processes rather than in isolated DRG cell
bodies.
Conclusions
Olvanil was effective at reducing capsaicin-induced ther-
mal hyperalgesia, likely via directly desensitizing TRPV1.
This effect was independent of CB1 receptor activation.
Although our findings cannot fully explain the lack of
pungency of olvanil, they clearly support the possibility
of employing olvanil to develop new topical treatments
for a wide range of chronic pain conditions, such as
arthritis, while overcoming the unwanted side effects of
the currently used capsaicin preparations.
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